Cassava Experiences Executive Turnover Over Controversial Alzheimer’s Drug
In recent months, Cassava Sciences, a biotech company known for its development of an Alzheimer’s drug, has been grappling with significant internal upheaval, marked by high-profile executive departures. This wave of turnover has been directly linked to the intense scrutiny and controversy surrounding its flagship drug, Simufilam. The challenges facing Cassava underscore a broader narrative […]